The cannabis sector is having a moment. After years of regulatory uncertainty and Washington cold shoulders, the AdvisorShares Pure U.S. Cannabis ETF (MSOS) is catching fire, with its momentum score rocketing from a lackluster 24.75 to an impressive 88.95 in just over a week.

Understanding the Momentum Surge

Momentum scores measure a stock's strength relative to peers by analyzing price movements and volatility across multiple timeframes, then ranking it on a percentile basis. When something jumps from the bottom quartile to near the top of the pack that quickly, people notice.

Two catalysts are driving this rally. First, the Trump administration's decision to reclassify marijuana is reshaping the industry's economics in a fundamental way. Second, Tilray Brands Inc. (TLRY) delivered strong earnings this week that reminded investors this sector has actual businesses with real revenue.

The Reclassification Game Changer

Here's why reclassification matters: under current tax rules, cannabis companies can't deduct ordinary business expenses the way normal companies can. It's a profitability killer. Reclassification changes that equation, allowing companies like Tilray to suddenly unlock significant cash flows by deducting standard business expenses. That's not a minor tweak—it's a fundamental shift in the economics of running a cannabis company.

Tilray clearly sees the opportunity. The company just unveiled Tilray Medical USA, a new medical subsidiary designed specifically to tap into what it calls the emerging "research-oriented national medical cannabis industry." That's corporate speak for "we're positioning ourselves to dominate the new regulatory landscape."

The result? Multiple holdings within the MSOS fund have rallied in the new year, with favorable price trends appearing across short, medium and long-term timeframes. When policy shifts from hostile to friendly, capital flows back in. It's that simple.

Whether this momentum sustains itself depends on how quickly regulatory changes translate into actual earnings improvements, but for now, investors are betting that Washington's warming attitude toward cannabis is more than just hot air.